Recent advances in the sophistication of HTA analysis and modelling, flexible pay for performance models, risk-sharing and value-based pricing schemes have become increasingly important to mitigate payer risk and allocate financial resources to the areas of pressing need. Savings and outcome improvements can also be found through finding efficiency gains at the healthcare delivery level, providing the right incentives for prescribers and improving patient adherence.
Against this backdrop, SMi鈥檚 21st annual European Pharmaceutical Pricing & Reimbursement conference, taking place on 5-6 October 2015 in London, will provide the ideal platform for payers and other decision makers from both public and private organisations, to benchmark with peers internationally and provide pharma companies with an invaluable insight into the decision making processes and approaches of these vital stakeholders. The two-day conference programme will help further your understanding and enable you to develop best practice approaches to such complex market access and pricing challenges, with the ultimate goal of encouraging innovation and improving patient access to novel and powerful medications.
Against this backdrop, SMi鈥檚 21st annual European Pharmaceutical Pricing & Reimbursement conference, taking place on 5-6 October 2015 in London, will provide the ideal platform for payers and other decision makers from both public and private organisations, to benchmark with peers internationally and provide pharma companies with an invaluable insight into the decision making processes and approaches of these vital stakeholders. The two-day conference programme will help further your understanding and enable you to develop best practice approaches to such complex market access and pricing challenges, with the ultimate goal of encouraging innovation and improving patient access to novel and powerful medications.
